For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the emergence of Tafamidis and the formulated version represents a true change. These novel therapies preserve the transthyretin protein, halting its harmful build-up and alleviating the burden of the disease . Individuals are now experiencing benefits in th